Table 2. Clinical Trials with Crizotinib in ALK-positive Patients
StudyPhasePatients with NSCLC, AKT+ (n)ORR (%)PFS (months)Author
PROFILE 1001Phase I14960.8 (95% CI, 52.3–68.9)9.7 (95% CI, 7.7–12.8)Camidge 2012
PROFILE 1005Phase II26160 (95% CI, 53.6–65.9)8.1 (95% CI, 6.8–9.7)Kim 2012
PROFILE 1007Phase III (CZT vs pemetrexed/docetaxel)34665 vs. 19.5*7.7 vs 3.0*Shaw 2013
PROFILE 1014Phase III (CZT vs cisplatin or carboplatin + pemetrexed)34374 vs. 45*10.9 vs 7.0*Mok 2014
  • * P < .0001.

  • CZT, crizotinib; CI, confidence interval; NA, not available; NSCLC, Non-small-cell lung cancer; ORR, objective response rate; PFS, progression-free survival.